Indium (In111) Oxinate Drn 4908 Curium Netherlands B.V.

Indium-111 oxine, the active ingredient in Indium (In111) Oxinate Drn 4908 Curium Netherlands B.V., is a radiopharmaceutical presented as a sterile solution for intravenous use. It is employed to label white blood cells for diagnostic imaging of infection, inflammation and certain tumors. GNH USA supplies Indium (In111) Oxinate Drn 4908 Curium Netherlands B.V. as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Indium-111 oxine is used in nuclear medicine to image sites of infection, inflammation and tumor activity. - Infection imaging: enables visualization of acute infection sites by labeling leukocytes. - Inflammatory disease assessment: helps locate inflammatory lesions such as osteomyelitis. - Tumor detection: assists in identifying certain tumors through radiolabeling of cells. - Granulomatous disease evaluation: aids in detecting sarcoidosis and related conditions. - Cardiac infection assessment: used to detect prosthetic valve endocarditis and other cardiac infections.

Adverse reactions may occur following intravenous administration of Indium-111 oxine.

Common Side Effects: - Injection site pain or erythema - Mild nausea or vomiting - Transient headache - Temporary flushing or warmth sensation - Mild hypotension - Low‑grade fever

Serious or Rare Side Effects: - Severe allergic reaction or anaphylaxis - Radiation‑induced bone marrow suppression - Significant hypotension requiring intervention - Pulmonary embolism from cell aggregates - Radiation‑induced malignancy (very rare) - Acute hemolysis or severe hemoglobin drop

Use of Indium-111 oxine requires careful consideration of radiation safety and patient condition. - Radiation exposure: limit unnecessary repeat imaging and follow institutional radiation protection guidelines. - Pregnancy: avoid use in pregnant patients unless the diagnostic benefit outweighs fetal radiation risk. - Breastfeeding: discontinue breastfeeding for an appropriate period after administration. - Allergies: contraindicated in patients with known hypersensitivity to indium‑111 oxine or any component of the preparation. - Hematologic status: assess bone marrow function before use, especially in patients receiving myelosuppressive therapy. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Indium-111 oxine may interact with other agents that affect imaging quality or patient safety.

Major Interactions (Avoid): - Concurrent administration of other radiopharmaceuticals that compete for the same imaging window. - High‑dose corticosteroids that suppress leukocyte function and reduce labeling efficiency. - Cytotoxic chemotherapy agents that cause profound bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased risk of bleeding at the injection site. - Iodinated contrast media: may alter image interpretation. - Immunosuppressants: may affect leukocyte labeling and distribution. - Beta‑blockers: can mask hypotensive responses. - Diuretics: may influence plasma volume and tracer kinetics.